- Home
- GAME vs LSB Comparison
GAME vs LSB Comparison
Compare GAME & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- LSB
- Stock Information
- Founded
- GAME 2011
- LSB 2002
- Country
- GAME United States
- LSB China
- Employees
- GAME N/A
- LSB N/A
- Industry
- GAME
- LSB
- Sector
- GAME
- LSB
- Exchange
- GAME Nasdaq
- LSB NYSE
- Market Cap
- GAME 27.2M
- LSB 22.3M
- IPO Year
- GAME 2009
- LSB N/A
- Fundamental
- Price
- GAME $0.85
- LSB $1.00
- Analyst Decision
- GAME Strong Buy
- LSB
- Analyst Count
- GAME 3
- LSB 0
- Target Price
- GAME $3.67
- LSB N/A
- AVG Volume (30 Days)
- GAME 433.5K
- LSB 14.1K
- Earning Date
- GAME 05-15-2025
- LSB 06-21-2025
- Dividend Yield
- GAME N/A
- LSB N/A
- EPS Growth
- GAME N/A
- LSB N/A
- EPS
- GAME N/A
- LSB N/A
- Revenue
- GAME $99,579,536.00
- LSB $79,415,311.00
- Revenue This Year
- GAME $6.08
- LSB $39.33
- Revenue Next Year
- GAME $21.94
- LSB $75.61
- P/E Ratio
- GAME N/A
- LSB N/A
- Revenue Growth
- GAME 77.06
- LSB N/A
- 52 Week Low
- GAME $0.50
- LSB $0.36
- 52 Week High
- GAME $1.43
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- GAME 58.35
- LSB 30.24
- Support Level
- GAME $0.86
- LSB $0.91
- Resistance Level
- GAME $0.92
- LSB $1.09
- Average True Range (ATR)
- GAME 0.07
- LSB 0.06
- MACD
- GAME 0.01
- LSB 0.02
- Stochastic Oscillator
- GAME 50.74
- LSB 29.03
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.